NOX-A12 (olaptesed pegol) is currently under development as a combination therapy in multiple oncology indications. The company is focused on a Phase 1/2 combination trial in metastatic pancreatic and colorectal cancer together with MSD’s KEYTRUDA®.
Other indications where NOXXON has developed plans for clinical development include brain cancer (glioblastoma/glioma) and multiple myeloma. NOX-A12 has received orphan drug designation for glioblastoma in the United States and glioma in Europe.

Mechanisms of action
NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine (signaling) protein. In cancer, it acts as a communication bridge or sign post between tumor cells and their environment, promoting tumor proliferation, new blood vessel formation and metastasis and reduces tumor apoptosis (cell death) (Source: Guo et al., 2015). NOX-A12 binds to two key sites in chemokine proteins to disrupt their activity and target them for destruction.

NOX-A12 is designed to fight tumors by modulating the tumor microenvironment in three distinct ways:

  • Break tumor protection enabling active immune cells, T-cells, to enter the tumor with the aim of unleashing the full potential of immuno-oncology approaches, such as immune checkpoint inhibitors*
  • Block tumor repair: through preventing the attraction of ‘repair cells’ to the tumors obstructing tumor re-growth
  • Expose hidden tumor cells: by inhibiting the formation of protective niches, leaving cancer cells in the blood stream where tumor killing drugs are more effective

    *Fearon, D. T. (2014). "The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance." Cancer Immunol Res 2(3): 187-193.

Recent clinical studie available at

  • Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559)
    (ref: NCT03168139)
    Status: ongoing

Recent NOX-A12 press releases

NOX-A12 press release archive

NOX-A12 publication archive